AUCKLAND NZ: December 5, 2019: New Zealand’s expertise in maternal and infant health research has led to the University of Auckland’s Liggins Institute and its research transfer company, Auckland UniServices, completing its first clinical trial, the CLIMB study, in collaboration with Chongqing Medical University (CQMU), in South-Western China.
“We are pleased to have reached this milestone and to see the exciting capability we have in China now. This successful
partnership paves the way for further trials and collaborations in the future. The results of the CLIMB study are also
expected to create potential economic benefits for the New Zealand dairy sector,” comments Auckland UniServices chief
executive Dr Andy Shenk.
The CLIMB (Complex Lipids in Mothers and Babies – Comparison of Different Maternal Milk Preparations during Pregnancy)
study, which was sponsored by Fonterra NZ and co-funded by the Primary Growth Partnership (PGP), was a first for CQMU
and was the first trial delivered by UniServices in China.
The three-year trial recruited 1500 pregnant women and started in 2015. It followed the progress of infants for a year
after birth. The trial explores the impact of mothers’ complex milk lipid intake on birth outcomes, infant brain
development and general maternal health. The researchers are currently analysing the results of the CLIMB trial.
“The project not only reflects the efficient assistance and advanced level of the research teams of both parties, the
Chongqing Medical University and the University of Auckland, but also reflects the strong leadership and sincerity of
the management of the two parties," says Professor Yang Zhu of the CQMU.
Chongqing is China’s most populous municipality (around 30 million) and its medical university was ranked ninth among
all Chinese medical universities in 2019. The University of Auckland is New Zealand’s leading university.
Despite Chongqing being home to such a large population, there has been little applied nutrition biomedical research
undertaken. The bio-banking facility and established patient database had to be introduced through the CLIMB study, and
the hard work of the CQMU project team to establish a clinical nutrition trial unit and experienced research nurses,
supported by UniServices’ project management expertise and Liggins Institute clinical trial expertise.
Biobank and database of the future
The resulting bio-bank and database now gives CQMU the chance to undertake hypothesis-generating research. It has serial
biosamples and metadata throughout pregnancy, and some limited infant and paediatric data.
“This means that we can study a variety of socio-demographic, clinical, haematological and biochemical parameters from
the perspective of pregnancy and infant outcomes. Bio-banks and metadata sets such as these can be “mined” for decades
and support further research,” says Professor Philip Baker, the trial’s co-investigator along with Professor Hongbo Qi.
Further strengthening CQMU’s capability is its Mass Spectrometry Laboratory, established in 2016 and directed by former
Liggins researcher Deputy Professor Ting–Li (Morgan) Han. With significant investment by CQMU, the centre aims to be
recognised globally as a pioneer in applying mass spectrometry technologies and bioinformatic analyses.
The laboratory undertook the analyses for the primary outcome of the CLIMB trial and has an increasing flow of internal
and external domestic and international contracts, including New Zealand and Singapore.
Future collaborations
The collaboration between UniServices and CQMU has been firmly established and opportunities for further research and
expansion of collaboration are being facilitated by a dedicated pregnancy research centre based at Chongqing. The centre
is attracting significant Chinese and New Zealand public good funding grants. The research facility houses the
International Pregnancy Research Alliance (IPRA) which brings together researchers from China, Canada, Ireland, the
United Kingdom, South America, Australia and New Zealand to nurture and develop pregnancy research in China.
One of the IPRA’s leading investigators is Dr Anna Ponnampalam (Liggins Institute). She is involved in projects with
CQMU collaborators who are looking at the role of the placenta in major pregnancy complications. PhD exchanges between
the Liggins Institute and CQMU have also provided valuable experience for students working on IPRA-related projects.
The University of Auckland's Innovation Institute China based in Hangzhou, the “Silicon Valley of China”, is
facilitating further engagements in commercial research, knowledge transfer and customised education services in China.
The capital of Zhejiang province and fourth-largest metropolitan area of China, Hangzhou is just an hour by bullet train
from Shanghai. The Institute was established by UniServices in 2017 as a wholly-owned subsidiary of the University of
Auckland.
It brings together people from all facets of the innovation ecosystem, including other New Zealand universities and
companies seeking to establish a footprint in China. Current collaboration activities include robotics, light metals,
technologies for clean water, energy and cities, drug development, particularly in oncology, high value nutrition and
clinical trials.